Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study

Table 1 Summary of demographic and baseline characteristics – ITT Population

Parameter	Category/ Statistics	Cohort 1 (N = 4)	Cohort 2 (N = 4)	Cohort 3 (N = 3)	All Patients (N = 11)
Age (years)	n	4	4	3	11
	Mean	73.0	76.5	79.3	76.0
	SD	11.40	6.14	5.51	7.96
	Median	78.0	75.5	79.0	79.0
	Min	56	71	74	56
	Max	80	84	85	85
Sex^(a)	Male, n (%)	1 (25.0)	2 (50.0)	2 (66.7)	5 (45.5)
Sex^(a)	Female, n (%)	3 (75.0)	2 (50.0)	1 (33.3)	6 (54.5)
Ethnicity	Hispanic/Latino, n (%)	4 (100)	4 (100)	2 (66.7)	10 (90.9)
Ethnicity	Not Hispanic/Latino, n (%)	0	0	1 (33.3)	1 (9.1)
Race	American Indian or Alaska Native, n (%)	0	0	0	0
	Asian, n (%)	0	0	0	0
	Black or African American, n (%)	0	0	0	0
	Native Hawaiian or Other Pacific, n (%)	0	0	0	0
	White, n (%)	4 (100)	4 (100)	3 (100)	11 (100)
	Other, n (%)	0	0	0	0
CDR-SB score	Median	10.0	11.25	10.0	10.0
	Min	4.5	4.0	6.0	4.0
	Max	13.0	18.0	18.0	18.0
ADAS-Cog score	Median	39.5	33.0	42.0	38.0
	Min	34.0	28.0	37.0	28.0
	Max	43.0	77.0	75.0	77.0
MMSE score	Median	13.5	16.5	14.0	14.0
	Min	13.0	3.0	2.0	2.0
	Max	23.0	21.0	21.0	23.0
ADCOMS score	Median	1.047	1.160	1.054	1.054
	Min	0.700	0.616	0.755	0.615
	Max	1.330	1.701	1.718	1.718
Biomarkers^(b)
CSF Aβ42 (pg/mL)	Median	324.16	278.33	352.91	323.23
	Min	198.39	247.54	262.72	198.39
	Max	473.37	503.58	368.57	503.58
CSF Aβ42/40 ratio	Median	0.0429	0.0457	0.042	0.0437
	Min	0.0404	0.0256	0.0379	0.0256
	Max	0.0642	0.056	0.0484	0.0642
CSF t-Tau (pg/mL)	Median	1043.51	830.59	703.72	767.16
	Min	435.47	653.23	702.56	435.47
	Max	1540.21	953.29	1418.55	1540.21
CSF p-Tau 181 (pg/mL)	Median	78.2	51.68	57.21	54.72
	Min	44.48	47.72	48.6	44.48
	Max	177	67.66	137.3	177
Plasma p-Tau217 (pg/mL)	Median	31.48	13.63	17.07	20.5
	Min	17.22	10.28	12.32	10.28
	Max	83.08	26.08	43.41	83.08

ISSN: 1758-9193